Skip to main content

ORIGINAL RESEARCH article

Front. Commun.

Sec. Health Communication

Volume 10 - 2025 | doi: 10.3389/fcomm.2025.1505456

Development and user testing of Gene Pilot: An electronic health decision support tool for Black cancer patients about tumor genomic profile testing

Provisionally accepted
Sarah Bauerle Bass Sarah Bauerle Bass 1*Yana Chertock Yana Chertock 2Jesse Brajuha Jesse Brajuha 1Patrick J.A. Kelly Patrick J.A. Kelly 1Alex Rotaru Alex Rotaru 1Paul D ' Avanzo Paul D ' Avanzo 1Ariel Hoadley Ariel Hoadley 1Caseem Luck Caseem Luck 1Katie Singley Katie Singley 1Michael J Hall Michael J Hall 2
  • 1 Temple University, Philadelphia, United States
  • 2 Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

The final, formatted version of the article will be published soon.

    Introduction: Tumor genomic profiling (TGP) is used to optimize cancer treatment but is underutilized by Black patients, despite having disproportionately higher cancer morbidity and mortality. No interventions using electronic health decision support tools (eHealth DSTs) have been developed to assist patients with understanding this test or address barriers to uptake and communicating preferences with a doctor. Methods: Using the Ottawa Decision Support Framework, we systematically developed the Gene Pilot eHealth DST with Black cancer patients. We conducted qualitative focus groups (5 groups, N=33) and surveys (N=121), elicited community advisory board feedback (N=10) to devise DST content and communication strategies, and then conducted user testing (N=10). Content was informed by commercial marketing techniques -segmentation, perceptual mapping, vector message modeling -to elucidate how medical mistrust was an important construct to address in Gene Pilot. Results: User testing (1-7 scale) indicated Gene Pilot was highly accepted, including ease of use (M=6.67, SD=.50), that it addressed important barriers such as medical mistrust and genetic literacy (6.63, SD=.52), and allowed patients to prepare for the decision (M=6.44, SD=.73) and to communicate with their doctor (M=6.33, SD=.73). Suggestions for improved navigability were addressed. Conclusion: Overall, Gene Pilot was found to be acceptable, suggesting its readiness for efficacy testing.

    Keywords: eHealth, Decision Support, Cancer, Genetic Testing, black/African American patients

    Received: 02 Oct 2024; Accepted: 21 Mar 2025.

    Copyright: © 2025 Bass, Chertock, Brajuha, Kelly, Rotaru, Avanzo, Hoadley, Luck, Singley and Hall. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Sarah Bauerle Bass, Temple University, Philadelphia, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more